Ryan Specialty Holdings IncRYAN
Price$38.39Intrinsic value$27.8627% below price

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.3%projected annual EPS growth
As of 27 Aug 2026
Analyst Coverage
16analysts covering
Consensus: PositiveAs of 18 Aug 2026
FY Revenue (est.)
$3.3Bnext fiscal year
As of 18 Aug 2026
FY EPS (est.)
$2.17next fiscal year
As of 18 Aug 2026
Reporting Calendar
EventExpected Date
Q3 2026 Earnings Release29 Oct 2026
Q4 2026 and Full-Year Earnings Release11 Feb 2027
Monitoring Framework
Key Performance Indicators
Organic Revenue Growth Rate Quarterly1,180.0%Target: Mid-single-digit organic growth for full-year 2026
Adjusted EBITDAC Margin Quarterly2,920.0%Target: Flat-to-moderately-down for full-year 2026 compared to 2025
Project Empower Cumulative Restructuring Charges AnnuallyTarget: Approximately $160 million cumulative one-time charges through 2028
Project Empower Annualized Cost Savings AnnuallyTarget: Approximately $80 million in annual savings by 2029
Watch Items
  • Property Insurance Market PricingTrigger: Pricing declines on large property accounts exceeding 25% to 35%Action: Accelerate expense management under Project Empower and shift capacity allocation toward firming casualty and specialty lines.
  • Casualty and Specialty Market CompetitionTrigger: Pricing normalization or increased capacity leading to a deceleration in casualty organic growth below mid-single digitsAction: Re-evaluate underwriting guidelines, leverage delegated authority relationships, and focus on high-hazard specialty niches.
  • Project Empower Restructuring ExecutionTrigger: Restructuring charges exceeding the $160 million budget or delays in standardizing operating platformsAction: Conduct a comprehensive operational audit of the integration process and adjust the timeline for platform consolidation.
Sign in / Sign up to read more

Research as of 2 Sep 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.